Galectin 1 (GAL1)
Galectin is a family of lectin superfamilies, widely distributed in various animals. Recently, researchers have discovered that a protein called GAL1 May be a potential therapeutic target for pancreatic cancer.
For the first time, researchers have shown that this protein is therapeutic in mice with pancreatic cancer, with results showing a 20 percent increase in survival. This work further suggests that GAL 1 May be a therapeutic target without adverse effects. So far, the strategy used to treat pancreatic cancer has been to attack tumor cells, with little success.
New research suggests that destroying the structures that surround tumours, the extracellular matrix, may be a better strategy. It is understood that GAL 1 is not found in normal pancreas, but is strongly expressed in pancreatic tumors. In addition, some studies have shown a relationship between GAL 1 and tumor progression.
The new study also observed that there were no harmful consequences for the elimination of GAL 1 in mice, suggesting it could be a safe therapeutic target with no adverse effects.
They observed that the tumors showed less proliferation, decreased blood vessels, less inflammation, and increased immune responses without the presence of galactin.All of these changes lead to less aggressive tumors.
At present, DLDEVELOP co. LTD has developed corresponding GAL1 Elisa products. To get more information, you could contact our professional staff directly or directly to our website:
https://dldevelop.com/Research-reagent/dl-gal1-b.html
https://dldevelop.com/Research-reagent/dl-gal1-hu.html
https://dldevelop.com/Research-reagent/dl-gal1-mu.html
https://dldevelop.com/Research-reagent/dl-gal1-p.html
https://dldevelop.com/Research-reagent/dl-gal1-ra.html
For the first time, researchers have shown that this protein is therapeutic in mice with pancreatic cancer, with results showing a 20 percent increase in survival. This work further suggests that GAL 1 May be a therapeutic target without adverse effects. So far, the strategy used to treat pancreatic cancer has been to attack tumor cells, with little success.
New research suggests that destroying the structures that surround tumours, the extracellular matrix, may be a better strategy. It is understood that GAL 1 is not found in normal pancreas, but is strongly expressed in pancreatic tumors. In addition, some studies have shown a relationship between GAL 1 and tumor progression.
The new study also observed that there were no harmful consequences for the elimination of GAL 1 in mice, suggesting it could be a safe therapeutic target with no adverse effects.
They observed that the tumors showed less proliferation, decreased blood vessels, less inflammation, and increased immune responses without the presence of galactin.All of these changes lead to less aggressive tumors.
At present, DLDEVELOP co. LTD has developed corresponding GAL1 Elisa products. To get more information, you could contact our professional staff directly or directly to our website:
https://dldevelop.com/Research-reagent/dl-gal1-b.html
https://dldevelop.com/Research-reagent/dl-gal1-hu.html
https://dldevelop.com/Research-reagent/dl-gal1-mu.html
https://dldevelop.com/Research-reagent/dl-gal1-p.html
https://dldevelop.com/Research-reagent/dl-gal1-ra.html
